- Medicon Valley
- News & Events
- News
- Bavarian Nordic Strengthens its Commercial Organisation and Updates on Pipeline Progress
- 2cureX a Novel Drug Discovery Company
- 7TM Pharma Receives Milestone Payment in Collaboration with Procter & Gamble Pharmaceuticals
- 7TM Pharma adds Johnson & Johnson Development Corp. to its Investor Group
- 7TM Pharma Enters Collaboration with Ortho-McNeil Pharmaceutical
- 7TM Pharma Initiates Phase II Clinical Study with Obinepitide
- 7TM Pharma Obtains Patent Protection for Obinepitide and TM30339
- 7TM Pharma Raises EUR 16.5 Million in Financing Round
- 7TM to Discover with Dr. Reddy's
- 7TM Pharma Acquires CareX
- 7TM Pharma’s Progress Attracts EUR 19 million in a Series C Financing Round
- 7TM Pharma’s Anti-Obesity Drug Completes Phase I/II Clinical Studies
- 7TM Pharma Initiates Clinical Trials for Treatment of Obesity
- 7TM Pharma Announces the Selection of a New Pre-Clinical Development Candidate
- 7TM Pharma Initiates Phase I/II Clinical Trial for TM30339
- 7TM Pharma Receives Milestone Payment from Asthma and Allergy Collaboration
- A Step Closer to a Vaccine against Atherosclerosis
- ACADIA Pharmaceuticals Expands Technology Platform
- ACADIA Pharmaceuticals Announces Positive Clinical Trial Results Demonstrating That ACP-103 Increases Slow Wave Sleep
- ACADIA Pharmaceuticals Announces Accelerated Timing of Phase II Trial
- ACADIA Announces Positive Results from ACP-103 Phase II Schizophrenia Co-Therapy Trial
- ACADIA Pharmaceuticals Identifies Molecular Properties of ACP-104
- ACADIA Pharmaceuticals Initiates Phase IIb Clinical Trial with ACP-104
- ACADIA Pharmaceuticals Initiates Phase III Trial with Pimavanserin
- Acadia Pharmaceuticals Adds Complementary Intellectual Property for Serotonin Platform
- ACADIA Pharmaceuticals Study Identifies Molecular Properties of ACP-104 That Predict Unique Antipsychotic Activity
- Action Pharma and Bachem Cooperate on AP214
- Action Pharma Raises EUR 15 Million from Investors
- Active Biotech and Chelsea Therapeutics in Collaboration
- Active Biotech Announces Successful Completion of Studies of ANYARA
- Active Biotech Enters Clinical Phase IIa Trial with RhuDex
- Active Biotech has Confirmed Localization of ANYARA in Cancer Patients
- Active Biotech Commences Clinical Phase I Combination Study
- Active Biotech Submits Patent Application Regarding the Mode of Action for Quinoline Compounds
- Active Biotech Presents New Pre-clinical Data for the 57-57 Project
- Active Biotech Receives Approval for phase II Studies of TASQ
- Active Biotech and Teva Initiate Pivotal Phase III Trial of Laquinimod
- Active Biotech's Phase I Study of SLE project 57-57 concluded
- Active Biotech Commences 57-57 Phase I Clinical Trial in Patients
- Active Biotech and Teva has Submitted an IND to the FDA
- Active Biotech gets Positive Clinical Results in Prostate Cancer Project TASQ
- Active Biotech Publishes Data Regarding the TASQ Cancer Project
- Active Biotech and Avidex Conclude Phase I Clinical Trials
- Active Biotech Receives 550000 Euro from Vinnova
- Active Biotech's ANYARA Granted Orphan Drug Status by EMEA
- Active Biotech to Start Enrolment in Phase III Study of Multiple Scleroses
- Agnitio Opens Sales Office in Germany
- ALK-Abelló Acquires Allerbio
- ALK-Abelló makes Breakthrough in Allergy Research
- ALK-Abelló to Acquire Schering's 50% Interest in German Subsidiary
- ALK-Abelló and Menarini Sign Agreement
- Alk-Abelló’s GRAZAX Approved in Sweden
- ALK-Abelló Launches GRAZAX on the First Market
- ALK-Abelló Launches Grazax in Sweden
- ALK-Abelló opens Allergy Research Centre in China
- ALK-Abelló Initiates Clinical Development Program with Ragweed Tablet
- ALK-Abelló Signs Partnership Agreement with Schering-Plough
- ALK-Abelló’s GRAZAX Approved in Europe
- Alligator Bioscience Concludes Project for AstraZeneca
- Alligator Bioscience Raises an Additional EUR 1.14 Million in Second Closing
- Alligator Bioscience has Reached a Successful Milestone
- Alligator Bioscience to Address Immunogenicity with Epibase
- Alligator Bioscience and SARomics Signs Collaboration Agreement
- Alligator Bioscience enters into Drug Development Collaboration
- Alligator Bioscience and ImmuRx Enter Into Strategic Collaboration
- Alligator Bioscience Launches FINDbind
- Ambria has Successfully Closed a Financing Round
- Lundbecks Antidepressant Project Lu AA21004 Moved Into Clinical Phase II
- Aresa has Joined First North Stock Exchange
- Arpida Announces Safe Results from Phase I Trial with Iclaprim
- Astellas Chooses Copenhagen as Nordic Headquarter
- Astion Pharma Enrolls for Phase III trials
- Astion Pharma Initiates Phase II Trial with ASF-1096
- Astion Pharma Raises EUR 5 Million in New Capital
- Astion Pharma Strengthens Capital Base
- Astion Pharma Begins Phase IIb Trial of ASF-1057 in Seborrheic Dermatitis
- Astion Pharma Initiates Phase II Clinical Study in Psoriasis
- AstraZeneca and Avanir Enter Global Alliance
- AstraZeneca and Schering Announce Collaboration and Licensing Agreement
- AstraZeneca Initiates Phase III Trials
- AstraZeneca has Acquired KuDOS Pharmaceutical
- AstraZeneca Signs Collaboration Agreement with Targacept for New Neuronal Nicotinic Receptor Compounds
- AstraZeneca and Astex announce new Anti-Cancer Drug Discovery Alliance
- AstraZeneca’s Symbicort Gives Improvement in Asthma Control
- Bavarian Nordic Announces Result of Efficacy Study
- Bavarian Nordic Continues with Imvamune Without GSK
- Bavarian Nordic Granted another European Patent on MVA
- Bavarian Nordic initiates Phase II clinical trials with IMVAMUNE
- Bavarian Nordic Initiates Phase I/II Trials with MVA-BN Against HIV
- Bavarian Nordic Receives Order on 20 Million Doses of Vaccine
- Bavarian Nordic to Deliver 20 Million Doses of IMVAMUNE
- Bavarian Nordic and Oxxon Therapeutics Cross-license MVA and PrimeBoost Patents
- Bavarian Nordic Establishes New Company in Washington, DC, USA
- Bavarian Nordic’s Kvistgård Facility Approved by Authorities
- Bavarian Nordic and the U.S. Government Extends RFP-2 Contract
- Bavarian Nordic and Acambis Settle All Legal Disputes on MVA
- Bavarian Nordic Receives EUR 35 Million Advance Payment from the U.S. Government
- Bavarian Nordic Receives US Notice of Allowance for New MVA-BN Patent
- Bavarian Nordic Starts Trial with Breast Cancer Vaccine
- Billion Potential for BioPorto within Diagnosis of Kidney Failures
- BioGaia Signs Agreement in Austria
- BioGaia Signs Agreement with Ferring Pharmaceuticals
- BioGaia Signs Agreement in France
- BioGaia Enters into Agreements for New Indication Area
- BioGaia signs Agreement for Hospital Distribution in the US
- BioGaia Signs Agreement with Novartis Consumer Health
- BioGaia Sells Oil to Canada and the Middle East
- BioGaia Signs Agreement for China
- BioGaia Signs Agreement for Germany
- BioGaia Signs Agreement for Indonesia
- BioGaia Signs Agreement for Oral Health Products in South Africa
- BioGaia Signs Agreement for Turkey
- BioGaia Signs Agreement in USA
- BioGaia Signs Agreement with Ewopharma
- BioGaia Signs Agreement with Semper
- BioGaia Signs Agreement with Sunstar
- BioGaia Signs Further Agreement with Ferring Pharmaceuticals
- BioGaia Signs New Agreement with Semper
- BioGaia Signs Agreement for Probiotic Oral Health Products in Scandinavia
- BioGaia Continues its Japanese Venture
- BioGaia´s Probiotic Oil Drops Reduce Hospital Stay
- BioGaia Signs Agreement with Major Oral Health Company
- BioGaia Signs Agreement for Belgium and Luxembourg
- BioGaia Signs Agreement in South America
- BioGaia Signs Agreement with Delta Medical
- BioGaia Signs Global Agreement for Oral Health Products
- BioGaia Signs new Agreement with Ferring Pharmaceuticals
- BioGaia In Stategic Alliance with Bericap
- Fisher Biosciences Strengthens Portfolio through Acquisition of BioImage
- Bioimaging Center in Lund Reciewes EUR 4.2 Million
- BioInvent and Lund University present Data on Significant Plaque Reduction in Blood Vessels
- BioInvent and Cambridge Antibody Technology sign Licensing Agreement
- BioInvent and ThromboGenics Awarded EU Grant
- BioInvent and ThromboGenics Receive Approval to Begin Phase I Trial
- BioInvent Designates Drug Candidate for the Treatment of Cancer
- BioInvent Enter Clinical Trials in UK
- BioInvent Enters Collaboration with Genentech
- BioInvent has Initiated Clinical Trials with Drug against HIV Infection
- BioInvent and Immusol to Collaborate on Antibody Therapeutic for Macular Degeneration
- BioInvent Implements a Secured Issue of Shares
- BioInvent Reassigns Rights to Develop Osteoarthritis Drugs to Cartela
- BioInvent Reports the Result from the Clinical Study in HIV
- BioInvent Issued US Patent for n-CoDeR Antibody Library
- BioInvent and Genentech Initiate Phase I Clinical Trial for BI-204
- BioInvent Signs Deal with Bayer HealthCare
- BioInvent and ThromboGenics Announce Successful Completion of Phase I Trial
- BioInvent and ThromboGenics Receive Approval to Begin Clinical Trials of TB-403
- Bioneer and Faculty of Pharmaceutical Sciences Establish New Drug Development Centre
- Biotech Boom in Medicon Valley
- Biovitrum and Symphogen Initiates Clinical Study with a Novel Treatment of Hemolytic Diseases
- Blood Sample Predicts the Effect of Colon Cancer Treatment
- BoneSupport granted FDA Approval for Injectable Bone Substitute
- BoneSupport Establishes Operations in the USA
- BoneSupport is Guaranteed EUR 1,6 Million in Approaching New Equity Issue
- BoneSupport Sells Polymer Patent to Mathys Ltd Bettlach
- Bonesupport Signs Distribution Agreement for the U.S. Market
- Bonesupport and Summit Corporate Services Finalize Agreement
- BRIC Researchers Identify Gene Essential for Stem Cell Differentiation
- BRIC Reveals How Cancer Cells Stay Forever Young
- Camurus Initiates Clinical Trial of Product Candidate in Patients with Oral Mucositis
- Camurus Starts Phase I Clinical Trial with CAM2029 – Octreotide Depot
- Camurus to Start Enrolment in Prostate Cancer Trial
- Camurus Receives Approval to Start Phase II Trial of CAM2028
- Nanonord acquires All Assets of Cantion
- CellaVision Delivers Products to Karolinska University Laboratory
- CellaVision Establishes Subsidiary in Japan
- CellaVision Listed on First North
- CellaVision Prolongs Cooperation with Kitron
- CellaVision Receives Order from St. Michael's Hospital
- CellaVision and Sysmex Extend Distribution Agreement
- CellaVision Analyzer Approved for Sale in Taiwan
- CellaVision Expands the Utility of the CellaVision DM96 Digital Morphology System
- CellaVision's New Application for Analysis of Body Fluids Pre-Launched
- Cellcure in Collaboration with Angel
- CellCure; develops T-cell based Cancer Therapy
- Celliance Enters Agreement with Novozymes
- Celltrix Receives Capital Infusion
- Intra-Group merger between Chr. Hansen Holding and ALK-Abelló
- Chr. Hansen Sells to Competitor
- CMC Acquires ICOS Biologics
- CMC Biopharmaceuticals Enters into Agreement with Syngenta Biopharma
- CMC Biopharmaceuticals receives EMEA Approval for In-market Manufacture
- CMC to Expand Under US Ownership
- Coloplast has Signed an Offer to Acquire Mentor Corporation’s Urology Business
- Confirmed Favourable Safety Profile for Active Biotech's oral MS drug
- Copenhagen Inventor Group Grants Exclusive License to Panagene
- Copenhagen University gets Funding for Three New Research Centres
- Copenhagen University Find Ways to Reveal the Extent of Bladder Cancer
- Copenhagen University Research Team to Secure Safe Blood Transfusions
- Curalogic and SAFC Signs Agreement
- Curalogic Enters Copenhagen Stock Exchange
- Curalogic is Expanding its Clinical Phase III Trial
- German Authorities Approve Plan for New Curalogic Product
- Cyncron and Harrison Clinical Research in Collaboration
- Dako Aquired by Private Equity Fund
- Dako Launches Innovative New System to Advance Cancer Diagnostics
- DakoCytomation and Clarient in Development Collaboration
- DakoCytomation and Clarient Sign Distribution and Development Agreement
- DakoCytomation becomes Dako
- DakoCytomation Licenses Anti-PTEN Antibody from MIT
- DakoCytomation Receives FDA Approval for c-Kit pharmDx
- DakoCytomation sharpens its Focus on Cell-Based Cancer Diagnostics
- Dako Enters New Collaboration on Targeted Therapies for NSCLC
- Dako Introduces Unique Package of RTU Antibodies for Cancer Diagnostics
- Dako Receives FDA Approval of Diagnostic Test for Breast Cancer Patients
- Dako’s Microbiology Business Acquired by Oxoid
- Danisco develops new groundbreaking enzyme
- Danish Breakthrough in Brain Cancer Treatment
- Danish Consortium to Secure Faster Development of New Medicine
- Danish Professor of Glycomics on top 10 List of Scientific Breakthroughs for 2007
- Danish Researchers Develop Blood Test to Reveal Downs Syndrome
- Danish Scientist Honoured for Research on NSAID Use in Heart Patients
- Danish Stem Cell Research to Cure Injured Knees
- Danish Researchers Identify Early Defence Protein Against Cancer
- Danish Scientist Discovers New Genes in Malaria Parasite
- Danish Winner of ERS COPD Research Awards 2007
- Denmark and Sweden Ranked 3rd and 4th in the Competitiveness Index
- DermaGen, a Novel Company Developing Antimicrobial Peptides
- DiLab enters Distribution Agreement with Bio Research Center
- DiLab Signs a Development and Purchase Agreement with Sanofi-Aventis Germany
- DuoCort Receives EU Orphan Drug Designation
- DuoCort Completes Enrolment for Pivotal Phase II-III Adrenal Insufficiency Trial
- DuoCort Completes Financing from Existing Shareholders
- DuoCort to Present Phase I Data at the European Congress of Endocrinology
- Egalet Secures Funding Through an International Financing Co-Led by Atlas Venture and Index Ventures
- Egalet Signs Agreement with SP Group
- Egalet Raises EUR 14,4 Million for Expanded Product Development
- Enkam has Successfully Completed Phase I Study
- Enkam and CHDI Enter Collaboration
- EUR 4 Million to Improved Animal Research in Copenhagen
- Euris to Establish new Incubator in Lund
- EuropaBio Elects Danish Steen Riisgaard New Chairman
- Evolva and AnalytiCon enter Nuclear Receptor Alliance
- Evolva Announces EUR 20.4 Million Award from the US DTRA
- Evolva Recieves $26.7 Million from USA
- Exiqon and Luminex Announce Development Agreement
- Exiqon Announces New Global Distribution Points
- Exiqon Expands in US
- Exiqon Wins Prestigious Ernst & Young Entrepeneur of the Year Award
- Exiqon Launches MicroRNA Detection Products
- Exiqon Listed on the Copenhagen Stock Exchange
- Exiqon to Acquire Oncotech
- Exiqon and Luminex Sign Distribution Agreement for MicroRNA Products
- Exiqon Signs a Cooperative Research and Development Agreement with NCI
- Ferring Pharma Initiates Phase III Trial with Degarelix
- Fluxome Sciences raises EUR 6 million in a Directed Equity Offering
- Formbion Enters Into Deal with Schering
- Gambro Acquires Clinics in Lithuania
- Gambro Acquires Hemapure
- Gambro and Nephrogen enter into new Partnership
- Gambro and Sandoz in Strategic Alliance
- Gambro Changes Structure to Strengthen Growth
- Gambro initiates Clinical Study for Platelets Treated with Mirasol Pathogen Reduction System
- Gambro enters Distribution and Promotion Agreement with Baxter
- Gambro BCT 7-Day Platelets will be Implemented by Blood Systems
- Gambro and DaVita Reach Agreement on Alliance and Product Supply
- DOR BioPharma Executes Letter of Intent for Acquisition of Gastrotech
- Gastrotech Completes Private Financing
- Gastrotech Initiates Clinical Phase II Cancer Cachexia Study
- Gastrotech Initiates New Clinical Phase II Cancer Cachexia Study
- Genmab Licenses Angiogenesis Targets from Bionomics
- Genmab and GlaxoSmithKline Enter Global Agreement
- Genmab and GSK’s Agreement for HuMax Receives Clearance
- Genmab and Serono announce Development and Commercialisation Agreement
- Genmab announces Positive Interim Results in Phase I/II HuMax-CD20 CLL Study
- Genmab to Become Member of Copenhagen Stock Exchange
- Genmab’s HuMax-EGFr Awarded Fast Track Status from FDA
- Genmab Reaches First Milestone in HuMax-TAC Agreement with Serono
- Genmab Initiates HuMax-CD20 Front Line CLL Study
- Genmab Initiates HuMax-CD20 Phase II Study in Rheumatoid Arthritis
- Genmab Initiates HuMax-EGFr Study in Non Small Cell Lung Cancer
- Genmab Initiates Ofatumumab Frontline NHL Study
- Genmab Licenses European and Asian Rights from Medarex
- Genmab receives Patent for HuMax-HepC
- Genmab Initiates HuMax-CD20 CLL Pivotal Study
- Genmab Regains Rights to HuMax-CD4
- Genmab Reports Positive Results
- Genmab in Research Cooperation with the DAHANCA-group
- Roche Files IND for Genmab Antibody
- Genmab Announces Update on AMG714 Programme with Amgen
- Genmab Amends HuMax-CD4 Pivotal Study in CTCL
- Genmab Antibody to Enter Phase II study to Treat Sarcoma
- Genmab and Bavarian Nordic Receives European Biotechnica Award
- Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program
- Genmab Announces HuMax-CD32B Pre-clinical Program
- Genmab’s Humax-CD38 Enters Phase I/II Clinical Trial for Multiple Myeloma
- Genmab Licenses MIF Receptor Target from Cytokine PharmaSciences
- Genmab and Pepscan in Research Collaboration
- Genmab Provides Insights into IgG4 Antibodies
- Genmab to Purchase Antibody Manufacturing Facility
- Genmab Reaches Milestones in Ofatumumab Collaboration
- Genmab Regains Rights to HuMax-TAC
- Genmab’s HuMax-CD20 Effective in Killing Tumor Cells
- Genmab’s partner Roche Files IND for Genmab Antibody
- Genmab’s Partner Roche Files CTA for Third Genmab Antibody
- Genmab’s Partner Roche Files IND for Fourth Genmab Antibody
- Genomic Expression Raises Funds for the Development of the DNA Bar-Code Technology
- Genovis Launches its First Product
- Genovis Launches US Operation
- Glycom and Nestlé Nutrition Enter into Agreement
- Glycorex Receives Order from Danish Hospital
- Glycorex’s Glycosorb-ABO Used to Complete Lung Transplant
- Grant for Cancer Research from the Leo Pharma Research Foundation
- Grant for Malaria Research
- Grant for Research into Metallothionins
- rant to Grant for Research into Tuberculosis
- Grant to Enkam to Research in Alzherimer’s Disease
- Grant to Research in Parkinson’s disease
- H. Lundbeck Enters Nalmefene License Into Force
- H. Lundbeck Initiates New Drug Candidate in Clinical Phase I
- H. Lundbeck publish Results from Cipralex Phase III Study
- Hagedorn Research Institute Receives Grant for Stem Cell Research
- H. Lundbeck exercises Co-Promotion Option in US
- iClin Announces Expansion of Product Family
- Innovation Team Opens Office in Medicon Valley
- KVL Heads Huge EU Research Project
- Launch of H. Lundbeck’s Azilect Commenced in Europe
- LifeCycle Pharma Announce FDA Approval of Reformulation of Fenofibrate
- LEO Pharma and Warner Chilcott Announce New Partnership
- LEO Pharma in Collaboration with Galapagos on Natural Compounds
- LEO Pharma Submits MAA for Daivobet Scalp gel
- LEO Pharma Supports Research
- LEO Pharma and Foamix to Develop Two new Medicated Foams for the Treatment of Psoriasis
- Leo Pharma Receives FDA Approval of Taclonex
- LEO Pharma inlicenses Atryn from GTC Biotherapeutics
- Leo Pharma Licenses Rights to Seocalcitol to Cougar Biotechnology
- LIDDS Completes EUR 4,4 Million Financing
- Lifecycle Pharma Enters the Copenhagen Stock Exchange
- LifeCycle Pharma to Initiate Phase II Clinical Trial of LCP-AtorFen
- LifeCycle Pharma Receives US Patent for its MeltDose Technology
- LifeCycle Pharma Signs Exclusive License Agreement with Schiele
- LifeCycle Pharma Enters Into Three Strategic Collaboration Agreements
- LifeCycle Pharma to Initiate Phase II Clinical Trial of LCP-Tacro
- LifeCycle Pharma Announces New Product Candidate
- LifeCycle Pharma Initiates Phase II Clinical Trial for LCP-Tacro
- LifeCycle Pharma Initiates Phase II Clinical Trial of LCP-Tacro for the Treatment of Autoimmune Hepatitis
- Ludesi Accelerates Growth through Innkap Investment
- Ludesi Secures a New Contract
- Ludesi wins Prestigious Contract
- Lund University and Others Release Analysis of Genes
- Lund University Appointed Excellent Centre for Rheumatic Research
- Lund University Professor Involved in Finding of New Gene Behind Diabetes
- Lund University Receives EUR 10 Million for Stroke Research
- Lund University Receives EUR 2.19 Million for Parkinson Research
- Lund University Receives Grant for Diabetes Research
- Lund University Receives Grant for Cancer Research
- Lund University Researchers Publishes a New Scientific Journal
- Lund University Starts New Innovation System, LUIS
- Identification of Protein Disturbing Effect of Breast Cancer Drug
- Lundbeck and PAION Partner on Desmoteplase for Acute Stroke
- Lundbeck Files Application for Approval of Cipralex in Treatment of OCD
- Lundbeck and BioTie Sign Agreement for Nalmefene
- H. Lundbeck and Danish Cancer Society in Novel Collaboration
- Lundbeck and Forest Uphold Lexapro patent
- Lundbeck Further Strengthens Pipeline by Moving Lu AA34893 into Phase II
- Lundbeck has Initiated Phase I Trials with Lu AA44608
- Lundbeck Initiates Phase I Clinical Trial with Lu AA24493
- Lundbeck Adds New Pharmaceutical Candidate in Pipeline
- H. Lundbeck Presents Data from a Phase II Clinical Trial
- H. Lundbeck; Launch of Serdolect Commenced in Europe
- Lundbeck’s Ebixa receives Extended Approval
- Lundbeck Adds New Pharmaceutical Candidate Lu AA37096 to Development Pipeline
- Lundbeck Enters Clinical Phase III with Lu AA21004
- Lundbeck Enters Clinical Phase II with Lu AA24530 for the Treatment of Mood and Anxiety Disorders
- Lundbeck Expands Geographical Rights for Circadin
- Lundbeck Initiates Phase I Clinical Trial with Lu AA47070 for Treatment of Parkinson's Disease
- Lundbeck In-licenses Circadin
- Lundbeck’s Cipralex Approved for the Treatment of OCD
- Lundbeck’s Lu AA21004 Shows Highly Significant Results in Clinical Phase II Trial
- Lundbeck and Takeda Form Alliance
- Lund University Study: Prediction of Type 2 Diabetes Risk
- Lund University Establishes New Bioincubator
- Lund University Research Team Finds Diagnostic Marker for Blood Cancer
- Lund University Respiratory Network Changes Asthma Perspective
- Major EU Grant for Analysis of Cancer Tissue
- Maxygen Initiates Phase IIa Clinical Trial of MAXY-G34
- Maxygen Initiates Phase I Clinical Trial
- Medical Prognosis Institute Enters Important Collaboration to Improve Cancer Treatment
- Medicon and Stem Cell Therapeutics Report Positive Results of Phase I Clinical Trial
- Medicon is Now Cyncron
- Medicon Opens its Second Office in Sweden
- Medicon Valley Based Valderm Receives Phase II Approval
- MediCult; Embryotech Laboratories to perform the Hybritest
- MediCult to conduct Proof-of-Concept Study for Novo Nordisk
- MediCult Completes Acquisition of Humagen
- MediCult enters into an Acquirement Agreement with CGA Strumenti Scientifici
- MediCult has In-licensed the Rights to Exploit the Compound IGF II
- MediCult has Signed Agreement with Laboratorios LETI S.L Unipersonal
- MediCult In-Licenses Active Compound to Increase ART Success Rates
- MediCult Launches New Device for Vitrification
- MediCult Obtains FDA 510k Clearance of EmbryoAssist
- MediCult Sells Directly in Austria
- MediCult Receives European CE Marking for IVF Media Product Line
- MediCult's Novel Media Promotes Adult Stem Cell Growth
- MediMush Secures Capital
- Medtentia Receives Intermediate Financing
- Medtentia Receives Capital Infusion
- Microlytic is Ready to Launch its First Product
- Millions to Danish Researchers from Bill Gates Foundation
- MIP Technologies and Supelco Launch a New Selective SPE Product
- MIP Technologies and Supelco Launch a New SPE product
- MIP Technologies Raises Capital
- MIP Technologies Launches Solid-phase Extraction Product for the Banned Antibiotic Chloramphenicol
- MIP Technologies and Supelco Launch a New Selective SPE Product
- MIP Technologies Signs Exclusive Distribution Agreement with Supelco
- Mycoteq a new Danish Biotech Company to Research in Micro Fungi
- MycoTeq Raises Money for Development of New Antibiotics
- Nanosep receives Novel Patent
- NatImmune Acquires Nya Hamlet Pharma
- NatImmune and Enzon enter into a License Agreement
- NatImmune Initiates Phase IIb Clinical Study with BAMLET Topical Gel
- The NeuroFortis Centre Receives Grant from Swedish Research Council
- NeuroLund, a novel Neuroscience Platform
- NeuroSearch Initiate Clinical Phase I Multiple Dosing Study
- NeuroSearch and GlaxoSmithKline Expand the Scope of Strategic Alliance
- NeuroSearch and GlaxoSmithKline Initiate Phase II
- Neurosearch Compound has Unexpected Anti-Obesity Effect
- NeuroSearch Receives Approval to Initiate a Phase IIb Study for Obesity
- NeuroSearch Updates on Clinical Development with NS1209
- NeuroSearch and GlaxoSmithKline Initiate Second Phase II Study
- NeuroSearch Initiates Phase I Clinical Study with ACR325
- NeuroSearch Initiates Phase I/II Clinical Study with Tesofensine in Obesity
- NeuroSearch to Acquire Carlsson Research
- NeuroSearch Announces Breakthrough Tesofensine Results
- NeuroSearch to Begin Clinical Phase III Programme with ACR16 in Huntington’s Disease
- NeuroSearch Initiates Clinical Phase I Study with ACR343 as a Treatment for Parkinson’s Disease
- NeuroSearch Initiates Clinical Phase I Study with NSD-644 as a Potential New Pain Treatment
- NeuroSearch Initiates Phase I Study with NSD-788 for the Treatment of Anxiety and Depression
- NeuroSearch’s License Partner Astellas Initiates Clinical Phase Ib Study
- NeuroSearch’s License Partner Abbott Initiates Clinical Phase II Study with ABT-894
- NeuroSearch’s License Partner Abbott Initiates Clinical Phase I Study with ABT-560
- NeuroSearch’s Partner Abbott Initiates Phase II Study with ABT-894 in Neuropathic Pain
- New Breast Cancer Network Founded in Denmark
- New Danish Drug Alliance
- New Anti-Diabetic Food Centre at Lund University
- New Centre for Epigenetics at University of Copenhagen
- New Danish Drug Company Raises EUR 17.6 Million
- New Innovation House at Lund University
- New Promising Results Published on Pharmexa's PADRE Epitope in Alzheimer's Vaccine
- NNE Acquires Germany-Based Pharmaplan
- Nordic Biotech raises Second Biotech Venture Fund
- Novo Nordisk and Neose Initiate Phase 1 Trial of Factor VIIa
- Novo Nordisk Announces Agreement with TransTech Pharma
- Novo Nordisk begins Phase 1 Study with rFXIII in Cardiac Surgery
- Novo Nordisk creates Biopharmaceuticals Research Unit
- Novo Nordisk Donates EUR 79 million to Danish Research
- Novo Nordisk Establishes Research Foundation in China
- Novo Nordisk Expands Manufacturing Facility in Clayton
- Novo Nordisk expands R&D Centre in China
- Novo Nordisk Increases Transparency on Clinical Trials and Bioethics
- Novo Nordisk and Innate Pharma Announce Strategic Partnership
- Novo Nordisk Launches Levemir in the United States
- Novo Nordisk Licenses Global Rights to Potential New Haemostasis Therapy
- Novo Nordisk’s Liraglutide Shows Positive Results in Phase III Study
- Novo Nordisk Strengthens Patent Position within Inhaled Insulin
- Novo Nordisk Receives Approval for Use of NovoRapid in Pregnancy
- Novo Nordisk receives EU Approval of Premixed Insulin Analogues
- Novo Nordisk, JDRF and EASD Join Forces in New Diabetes Research Programmes
- Novo Nordisk Receives Approval in the EU for Use of NovoRapid in Elderly People
- Novo Nordisk's Levemir Approved in Europe
- Novo Nordisk Announces Initiation of Three New Clinical Studies
- Novo Nordisk and Argos Therapeutics Announce Agreement
- Novo Nordisk and G2 Therapies Announce Global Research, Development and License Agreement
- Novo Nordisk Opens the First Haemostasis Research Facility in the US
- Novo Nordisk Inaugurates Insulin Plant in Brazil
- Novo Nordisk Inaugurates new Production Plant in China
- Novo Nordisk Reinitiates Phase III Programme for Inhalable Insulin Project
- Novo Nordisk Receives US Approval of Levemir
- Novo Nordisk Donates Compound Library to Chinese Pharmaceutical Development and WHO
- Novo Nordisk Announces that Liraglutide Leads to Significant Weight Loss in Obese People
- Novo Nordisk and Millipore Expand Agreement
- Novo Nordisk is Rated Supersector Leader in the 2007 Dow Jones Sustainability Indexes
- Novo Nordisk Receives Approval for Levemir in Japan
- Novozymes to Acquire the Enzyme Business of Biocon India
- Novozymes Aquires Delta Biotechnology Ltd
- Novozymes Acquires GroPep Ltd.
- Novozymes Enters Development for Biofuel in China
- Novozymes Creates a New Biopharmaceutical Ingredients Business
- Novozymes is Expanding in India
- Novozymes launches New Blood Removing Enzyme
- Novozymes No. 1 for Sustainability
- Novozymes Opens Office in Washington
- Novozymes Recognized for new Antibiotic against Resistant Bacteria
- Novozymes Announces Progress in Development of Weapon Against Resistant Staphylococci
- Novozymes and Cargill Signs Acid Agreement
- Novozymes Completes Aqcquisition of Enzyme Activities of Biocon
- Novozymes Launches Enzyme to Reduce Acrylamide in Food
- Novozymes and Millipore Corporation Form Strategic Alliance
- Novozymes Transfers Manufacture of LONG-R3-IGF-I to Lund
- NsGene and Genzyme Enter into Agreement on NsG33
- NsGene receives Milestone Payment from Biogen Idec
- NsGene Begins Phase Ib Clinical Trial with NsG0202 for Treatment of Alzheimer’s Disease
- NsGene’s Restorative Alzheimer’s Product has Successfully Been Implanted in Patients
- Nuevolution and Biovitrum in Drug Discovery Collaboration
- Nuevolution Signs Agreement with Schering on Drug Discovery
- Nycomed Acquires Romanian Pharmaceutical Company
- Enrolment of 13,800 Patients completed in Global Trial of Angiox
- Nycomed Achieves European Approval of Preotact
- Nycomed Expands Preotact Deal
- Nycomed Market Expansion into Spain and Portugal
- Nycomed to Market Circadin for Primary Insomnia
- Nycomed; Positive CHMP Opinion - Preotact Moves closer to European Approval
- Nycomed to Acquire Altana Pharma
- Nycomed Common Cold Product ZyComb First Approved in Sweden
- Nycomed and Durect Corporation Announce Licensing Agreement
- Nycomed Files Marketing Authorisation Application for an Intranasal Fentanyl Spray in Europe
- Nycomed’s Venticute Granted “Fast Track” Designation in the US
- Osteologix Commences Phase I Clinical Trials
- Osteologix Completes Enrolment in Trial of Drug for Osteoporosis
- Osteologix Completes Phase I Clinical Trials
- Osteologix Initiates Phase II Trial with NB S101 against Osteoporosis
- Osteologix Completes Reverse Merger
- Pharmexa is awarded DnB NORs Innovation Award, Denmark-Norway
- Pharmexa and Affitech Enter into an Exclusive License Agreement
- Pharmexa and Bavarian Nordic Initiates Phase I Trial
- Pharmexa and Ichor Medical Systems Enter Into a License Agreement
- Pharmexa Obtains Approval in Russia
- Pharmexa Files the first Phase III Application
- Pharmexa Subsidiary in Novel Collaboration on Translational Research
- Pharmexa Granted Orphan Drug Designation for GV1001 in Europe
- Pharmexa obtains Global License to use Provax from Biogen Idec
- Pharmexa Starts PrimoVax Phase III Trial
- Pharmexa: Promising preliminary results with breast cancer vaccine
- Pharmexa Receives Approval to Start Phase Ib Trial with HIV Vaccine
- Pharmexa will start phase II trial in liver cancer with GV1001
- Pharmexa Starts Pivotal Phase III Trial in the United States
- Pharmexa Again Prevails Against Geron in Patent Appeal
- Pharmexa Announces Promising Clinical Results from New HIV Vaccine
- Pharmexa to Acquire Assets from IDM Pharma and Establishes US Subsidiary
- Pharmexa Starts Phase I Trial in HIV together with HVTN
- Pharmexa-Epimmune and Ichor Medical Systems Enter Agreement
- Pharmexa Extends and Updates License Agreement with Lundbeck
- Pharmexa Grants PADRE License to ImmunoVaccine Technologies
- Pharmexa Receives Patent in the US and Europe on Vaccine Candidate
- Pharmexa Initiates Phase II Trial in Liver and Lung Cancer with GV1001
- Pharmexa’s GV1001 Begins Phase III Trial for Pancreatic Cancer
- PhaseOneTrials Enters Agreement with Schering Plough
- PhaseOneTrials Initiates Phase I Study
- Phaseonetrials Listed on First North
- Positive Results with in vitro Cancer Vaccine
- PPD Opens Office in Copenhagen
- Preclinical Data Presented for Active Biotech's ANYARA Technology
- Probi Expans the Distribution of Probiotic
- Probi Signs Agreement for the American Market
- Probi’s Probiotic Bacteria Reduces Iron Deficiency
- Pronova BioPharma to Construct a New Manufacturing Facility in Kalundborg
- ProstaLund; Treatment with Microwaves still Going Strong after 5 Years
- Quickcool Secures Funding
- Covalent Group Enters into Combination Agreement with Remedium
- Research Grant for Cancer Gene Therapy
- Large Research Grant for Research into microRNA
- Researchers from Lund University Initiate EU Projects within Stroke
- Researcher Receives Grant for Research into Psoriasis
- Research Grant for Cancer Gene Therapy
- Rheoscience and Dr. Reddy’s Laboratories in Novel Agreement
- Rheoscience and Dr. Reddy’s Initiate the First Phase III Trial of Balaglitazone
- Santaris Pharma and Enzon to Develop Novel Cancer Therapeutics
- Santaris Pharma and GlaxoSmithKline Enter Global R&D Alliance
- Santaris Pharma Awarded Ernst & Young Entrepreneur of the Year 2006
- Santaris Pharma Consortium Awarded EUR 1.35 Million
- Santaris Pharma Initiates Clinical Trial in CLL
- Santaris Pharma Raises Funding from Lead Investors
- Santaris Pharma Recives Milestone Payment
- Santaris Pharma’s HIF-1 Alpha Antagonist Begins Second Phase 1 Study
- Santaris Pharma Raises New Equity
- Santaris Pharma; FDA approves IND for SPC2996 in CLL
- Santaris Pharma Raises EUR 20 Million of New Equity
- Sartorius Stedim Biotech Sets up Nordic HQ in Copenhagen
- Scandinavian Success at BIO2007
- SchizoDetect AB Receives EUR 170,000
- SchizoDetect Develops new Diagnostic Evaluation Tool
- Scientist at Lund University Wins Nordic Fernström Prize
- Sophion Bioscience Collaborates with Merck on 48-Channel Gigaseal Patch Clamp System
- Sophion Inc. moves into New Jersey Technology Centre
- Sophion to Sell CHO-hERG Cell Line Optimized for the QPatch Automated Patch Clamp System
- SpectraCure to Receive Millions as Investment in Cancer Treatment
- Statens Serum Institut and Sanofi Pasteur Join Forces to Combat Tuberculosis
- Large Investment into Strategic Research in Lund
- Survac acquired by Merck
- Sweden and Denmark in Top 5 of the European Innovation Scoreboard 2007
- Symbion Receives International Award as Best Science Park Incubator 2005
- Symphogen and Cambridge Antibody Technology sign Patent Licensing Agreement
- Symphogen Attracts new Million Investment
- Symphogen and Biovitrum Enter Novel Collaboration Agreement
- Symphogen and Biovitrum Initiate Phase I Clinical Trial of Sym001
- Symphogen in Collaboration with Meiji
- Symphogen Gains Investment from Dutch Venture Capital Fund
- Symphogen Granted New Allergy Patent
- Symphogen has been Granted New Manufacturing Patent
- Symphogen and Biovitrum have Successfully Completed Phase I Trial with Recombinant Polyclonal Antibody
- Symphogen Elected as Denmark’s Best Biotech Company
- Symphogen Issued Patent Covering Symplex Technology
- Synarc to Combine with Centre for Clinical and Basic Research
- TATAA Biocenter Established Centre in Prague
- T-cellic Reaches Milestone in Cancer Research
- Teknoseed secures EUR 5,3 million in New Early Stage VC fund
- The Lundbeck Foundation Donates EUR 134 Million to Danish Research
- The Sale of Gambro Healthcare US to DaVita has Closed
- The Øresund Science Region is Number One in the EU RegioStars Award
- TopoTarget and CuraGen Initiate Phase II Clinical Trial of PXD101 for AML
- TopoTarget and CuraGen Initiate Phase I/II Clinical Trial of Belinostat in Combination with Doxorubicin
- TopoTarget and CuraGen Out-License Rights for Preclinical HDAC Inhibitor
- TopoTarget and CuraGen Initiate Phase II Trial for Ovarian Cancer
- TopoTarget and CuraGen Present Encouraging new Preclinical Data on PXD101 at the AACR 97th Annual Meeting
- TopoTarget and NeuroSearch expand collaboration within Cancer Treatment
- TopoTarget Announces Allowance of Valproic Acid Patent in Europe Covering Savicol
- TopoTarget Finalises Purchase of BioImage Compounds
- TopoTarget Completes the Acquisition of Apoxis SA
- TopoTarget and CuraGen Announce Initiation of first NCI-Sponsored Clinical Trial with PXD101
- TopoTarget and CuraGen initiate Phase Ib Clinical Trial
- TopoTarget and CuraGen Initiate Phase I Trial of PXD in Tumour Patients
- TopoTarget and CuraGen Initiate Phase II Trial with PXD101 for T-Cell Lymphomas
- TopoTarget and CuraGen initiate Phase I/II for Hepatocellular Cancer
- TopoTarget and CuraGen Initiate Phase II Clinical Trial with PXD101 for Mesothelioma
- TopoTarget and CuraGen Initiate Phase I Trial with PXD101
- TopoTarget and CuraGen Initiate Phase Ib/II trial with PXD101 in Combination with Velcade for Multiple Myeloma
- TopoTarget Enters Copenhagen Stock Exchange
- TopoTarget Establishes TopoTarget USA, Inc.
- TopoTarget expands Pipeline with novel Class of Cancer Therapeutics from BioImage
- TopoTarget has Received an Approvable Letter for Totect
- TopoTarget initiates Phase II Proof-of-Concept Study
- TopoTarget Initiates Phase II Clinical Trial with Avugane
- Topo Target Launches Savene Ahead of Scheldule
- TopoTarget Launches Totect in the US
- TopoTarget Receives Marketing Approval of Totect
- TopoTarget and CuraGen Initiate Phase II Clinical Trial of PXD101
- TopoTarget Receives Broad US and EU Patents for Key HDAC Inhibitors
- TopoTarget receives Milestone Payment from CuraGen
- TopoTarget Reports Promising Phase II Trial Results with Avugane in Acne Vulgaris
- TopoTarget Enters Promotion Agreement for Savene
- TopoTarget Initiates Pivotal Phase II Trial with Savicol
- TopoTarget Acquires US & RoW Rights from CuraGen Corporation
- TopoTarget Announces Award of Two Key Patents
- TopoTarget and CuraGen Initiate Phase II Trial with PXD101 for Lymphoma
- TopoTarget and CuraGen Announce Expansion of Clinical Trial
- TopoTarget and CuraGen Initiate Phase I/II Trial of Belinostat for Acute Myeloid Leukemia
- TopoTarget and CuraGen Initiate Phase II Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma
- TopoTarget and CuraGen Initiate Clinical Trial of PXD101 and Azacytidine
- TopoTarget and CuraGen Initiate Phase II Trial of Belinostat in Combination with Velcade
- TopoTarget Executes its Licensing Option for the Development of Zemab
- TopoTarget and Lundbeck Sign Agreement for Siramesine
- TopoTarget’s New Antidote Savene Becomes Gold Standard
- TopoTargets Savene Approved in Europe
- TopoTarget’s Savene Recommended Treatment for Anthracycline Extravasation
- TopoTarget’s Totect Approved in the United States
- TopoTarget Announces APO010 Patent Allowed in the USA
- Trial Form Support Acquires Clinical Data Care
- UCB Concentrates Nordic Activities in Copenhagen
- UMAS Tests New Meningitis Vaccine
- University of Copenhagen and CLC Bio Sign Site License Agreement
- University of Copenhagen and PerkinElmer Inc in Licensing Agreement
- UpFront in Collaboration with Solanic
- Upfront Chromatography in Development Agreement with Cangene Corporation
- Vaginal Probiotic Product Reduces Recurrence Rate of Bacterial Vaginosis
- Valderm Receives Funding for Innovative Psoriasis Therapy
- VersaMatrix Launches Versaffin for Affinity Resin-Mediated Bioseparation
- Vipergen Develops New Drug Discovery Technology Platform
- Vipergen has been Nominated as World Economic Forum Technology Pioneer 2008
- ViroGates’ HIV Monitoring Kit to be Implemented in Denmark
- ViroGates Completes Development of First-In-Class HIV Prognostic Kit
- ViroGates Oversubscribes three Times Its Latest Private Round
- ViroGates Receives CE Mark on its In-vitro Diagnostics Test for HIV Monitoring Test
- ViroGates Closes New Financing Round of EUR 2 million
- ViroGates Launches the SuPARnostic ELISA Test Kit to the European Market
- Vivolution Receives EUR 7.5 Million
- Vivolution Acquires Extensive Patent Portfolio from Bristol-Meyers Squibb
- Zacco Acquires the Majority in Ipendo
- Zealand Pharma completes Second Stage of its International Financing
- Zealand Pharma Initiates Phase II Efficacy Study in Patients with Acute Decompensated Heart Failure
- Zealand Pharma Raises Capital
- Sanofi-Aventis Initiates ZP10 Phase II Trial
- Zealand Pharma’s IND for ZP1846 Approved by FDA
- Zgene Enters License Agreement with Lentigen Corporation
- Zymenex Granted European Patent
- Zymenex Gets US Orphan Approval
- Zymenex Initiates Phase II Trial of Metazym in Children with MLD
- Zymenex Receives Grant
- Zymenex Sells Clinical Candidate Metazym to Shire for EUR 85.6 Million
- Events
- Medicon Valley Newsletter
- Business Opportunities
- Science & Research
- Networks
- Services & Support
- Companies & Institutions
- At Your Service
